- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06667687
Undersøgelse for at evaluere uønskede hændelser, ændring i sygdomsaktivitet og hvordan intravenøst infunderet ABBV-291 bevæger sig gennem kroppen hos voksne deltagere med non-Hodgkins lymfom
Et fase 1 første-i-menneske-studie, der evaluerer sikkerhed, farmakokinetik og effektivitet af ABBV-291 i non-Hodgkins lymfom
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-291 in adult participants in relapsed or refractory (R/R) NHL, including but not limited to diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). Adverse events will be assessed.
ABBV-291 is an investigational drug being developed for the treatment of NHL. This study will include a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-291 and a dose expansion/optimization phase to determine the change in disease activity in participants with R/R NHL. Approximately 165 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide
In the dose escalation phase of the study participants will receive escalating Intravenously (IV) infused doses of ABBV-291, until the MAD/MTD is determined. In the dose expansion/optimization phase of the study participants receive IV infused ABBV-291, as part of the approximately 74 month study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Victoria
-
Fitzroy Melbourne, Victoria, Australien, 3065
- St Vincent's Hospital Melbourne /ID# 261664
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Sir Charles Gairdner Hospital /ID# 268579
-
-
-
-
-
Manchester, Det Forenede Kongerige, M20 4BX
- The Christie /ID# 267177
-
Plymouth, Det Forenede Kongerige, PL6 5FP
- University Hospitals Plymouth NHS Trust /ID# 267174
-
-
-
-
North Carolina
-
Huntersville, North Carolina, Forenede Stater, 28078
- Carolina BioOncology Institute /ID# 265259
-
-
Oregon
-
Eugene, Oregon, Forenede Stater, 97401
- Willamette Valley Cancer Institute and Research Center /ID# 270945
-
-
Texas
-
Austin, Texas, Forenede Stater, 78705
- Texas Oncology - Central/South Texas /ID# 270946
-
-
Utah
-
West Valley City, Utah, Forenede Stater, 84119-3602
- START Mountain Region /ID# 267592
-
-
Virginia
-
Fairfax, Virginia, Forenede Stater, 22031
- Virginia Cancer Specialists - Fairfax /ID# 265082
-
-
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 91120
- Hadassah Medical Center-Hebrew University /ID# 261658
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Israel, 6423906
- Tel Aviv Sourasky Medical Center /ID# 261659
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japan, 464-8681
- Aichi Cancer Center /ID# 267471
-
-
Chiba
-
Kashiwa-shi, Chiba, Japan, 277-8577
- National Cancer Center Hospital East /ID# 261775
-
-
Tokyo
-
Koto-ku, Tokyo, Japan, 135-8550
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 267470
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
For dose escalation (Part 1) only: Participants must have documented diagnosis of B-cell malignancies including (but not limited to) the following, with histology based on criteria established by the World Health Organization (WHO), and measurable disease requiring treatment:
- Mantle cell lymphoma (MCL);
- Marginal zone lymphoma (MZL);
- Waldenstrom macroglobulinemia (WM);
- Diffuse large b-cell lymphoma (DLBCL) (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL [leg type], Epstein-Barr virus-positive (EBV+) DLBCL [not otherwise specified], DLBCL associated with chronic inflammation, human herpesvirus 8-positive [HHV8+] DLBCL [not otherwise specified], B cell lymphoma [unclassifiable] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma [not otherwise specified], high-grade B-cell lymphoma [with MYC (avian myelocytomatosis viral oncogene homolog) and BCL2 and/or BCL6 rearrangements], DLBCL arising from follicular lymphoma [FL] [transformed FL]);
- FL Grades 1 to 3B;
-
For dose expansion (Part 2) only: Participants must have documented diagnosis of one of the following B-cell malignancies, with histology based on criteria established by the WHO, and measurable disease requiring treatment:
- Part 2a only: DLBCL (including: germinal center B-cell type, activated B-cell type, primary cutaneous DLBCL [leg type], EBV+ DLBCL [not otherwise specified], DLBCL associated with chronic inflammation, HHV8+ DLBCL [not otherwise specified], B-cell lymphoma [unclassifiable] with features intermediate between DLBCL and classical Hodgkin lymphoma, high-grade B-cell lymphoma [not otherwise specified], high-grade B-cell lymphoma [with MYC and BCL2 and/or BCL6 rearrangements], DLBCL arising from FL [transformed FL]);
- Part 2b only: FL Grades 1 to 3B;
- Part 2c only: Mantle cell lymphoma;
-
For all participants (Parts 1 and 2):
-
Must be considered relapsed or refractory to, or intolerant of, at least 2 or more prior lines of therapy known to provide a clinical benefit for their condition, and for whom there is no appropriate locally available therapy known to provide clinical benefit (e.g., standard chemotherapy or autologous stem cell transplantation [ASCT]).
-
Indolent non-Hodkin's lymphoma (NHL) participants must meet relevant disease specific requirements for treatment (e.g., National Comprehensive Cancer Network [NCCN], Groupe d'Etude des Lymphomes Folliculaires [GELF]).
-
History of allogeneic stem cell transplantation must be stable off of immunosuppression for at least 3 months.
-
For participants enrolled in backfill cohorts or at dose levels previously cleared, subjects must provide consent to an on-treatment fresh tumor biopsy from the same tumor lesion as the baseline tumor tissue. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.
-
Previously treated with a CD79b-targeting therapy (e.g., CD79b monoclonal antibody) a core or excision tumor biopsy subsequent to the most recent CD79b-targeting therapy must be collected. Tumor biopsy requirements may be modified by Sponsor during the study. This requirement may be waived at the discretion of the contract research organization (CRO) Medical Monitor if collecting a biopsy would place the subject at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a subject's ability to participate in the study.
- CD79b expression status will be assessed in all participants.
-
-
Have an eastern cooperative oncology group (ECOG) Performance Status of 0 or 1.
-
Laboratory values meeting the criteria in the protocol within the screening period prior to the first dose of study drug (if multiple samples are drawn within the screening period, the sample/result immediately prior to Cycle 1 Day 1 is applicable).
-
Availability of representative baseline tumor tissue (most recent archived tumor tissue or fresh biopsy collected during screening phase) suitable for immunohistochemistry (IHC) testing. This requirement may be waived at the discretion of the CRO Medical Monitor if collecting a biopsy at screening would place the participant at risk of harm or would require a technically complicated procedure based on tumor location as assessed by the investigator or could hinder a participant's ability to participate in the study.
Exclusion Criteria:
-
History of interstitial lung disease (ILD) or pneumonitis that required treatment with systemic steroids, or any evidence of active ILD or pneumonitis.
-
Treatment with any of the following:
- Anticancer therapy including chemotherapy, radiotherapy, small molecule, investigational, and biologic agents within 14 days (or at least 5 half-lives, whichever is shorter), prior to the first dose of the study treatment;
- CD79b-directed agents (e.g., CD79b monoclonal antibody therapy) within 4 weeks (or at least 5 half-lives, whichever is shorter) prior to the first dose of study treatment.
- Prior treatment with an antibody drug conjugate that consists of a topoisomerase I inhibitor.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Escalation: Non-Hodgkin Lymphoma (NHL) ABBV-291
Participants with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), except chronic lymphocytic leukemia (CLL), will receive escalating doses of ABBV-291, as part of the 74 month study duration. |
Intravenous Infusion |
|
Eksperimentel: Expansion: Diffuse Large B-Cell Lymphoma (DLBCL) ABBV-291
Participants with R/R DLBCL will receive the recommended Phase 1 expansion dose (RP1ED) of ABBV-291, as part of the 74 month study duration. |
Intravenous Infusion |
|
Eksperimentel: Expansion: Follicular Lymphoma (FL) ABBV-291
Participants with R/R FL will receive the RP1ED of ABBV-291, as part of the 74 month study duration. |
Intravenous Infusion |
|
Eksperimentel: Optimization: Mantle Cell Lymphoma (MCL) ABBV-291 Dose A
Participants with R/R MCL will receive the dose A of ABBV-291, as part of the 74 month study duration. |
Intravenous Infusion |
|
Eksperimentel: Optimization: MCL ABBV-291 Dose B
Participants with R/R MCL will receive the dose B of ABBV-291, as part of the 74 month study duration. |
Intravenous Infusion |
|
Eksperimentel: Optimization: MCL ABBV-291 Dose C
Participants with R/R MCL will receive the dose C of ABBV-291, as part of the 74 month study duration. |
Intravenous Infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Percentage of Participants with Adverse Events (AE)s
Tidsramme: Up to 74 Months
|
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. |
Up to 74 Months
|
|
Percentage of Participants with Dose Limiting Toxicities (DLT)s
Tidsramme: Up to 74 Months
|
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications. |
Up to 74 Months
|
|
Percentage of Participants with Clinically Significant Laboratory Values (Chemistry, and Hematology)
Tidsramme: Up to 74 Months
|
Percentage of participants with clinically significant laboratory values (chemistry, and hematology). |
Up to 74 Months
|
|
Percentage of Participants with Clinically Significant Vital Sign Measurements
Tidsramme: Up to 74 Months
|
Vital sign are defined as determinations of systolic and diastolic blood pressure, pulse rate, respiratory rate, and body temperature. |
Up to 74 Months
|
|
Percentage of Participants with Clinically Significant Electrocardiogram (ECG) Findings
Tidsramme: Up to 74 Months
|
Percentage of participants with clinically significant ECG findings. |
Up to 74 Months
|
|
Objective Response Rate (ORR)
Tidsramme: Up to 74 Months
|
ORR is defined as the percentage of participants with a confirmed best overall response (BOR) of partial response (PR) or better per disease-specific response criteria (e.g., Lugano classification). |
Up to 74 Months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Duration of Response (DOR) as Assessed by Investigator
Tidsramme: Up to 74 Months
|
DOR is defined for participants achieving a confirmed PR or better as the time from the initial response of PR (or better) per investigator review according to disease-specific response criteria to disease progression or death of any cause, whichever occurs earlier. |
Up to 74 Months
|
|
Progression-Free Survival (PFS) as Assessed by Investigator
Tidsramme: Up to 74 Months
|
PFS is defined as time from first study treatment to a documented disease progression according to disease-specific response criteria, as determined by the investigator, or death due to any cause, whichever occurs earlier. |
Up to 74 Months
|
|
Time to response (TTR)
Tidsramme: Up to 74 Months
|
TTR is defined as time from first study treatment to the initial response of PR (or better) per investigator review according to disease-specific response criteria. |
Up to 74 Months
|
|
Area Under the Curve (AUC) of ABBV-291
Tidsramme: Up to 12 Months
|
AUC is defined as the area under the plasma/serum concentration-time curve of ABBV-291. |
Up to 12 Months
|
|
Maximum Observed Plasma/Serum Concentration (Cmax) of ABBV-291
Tidsramme: Up to 12 Months
|
Cmax is defined as maximum observed plasma/serum concentration of ABBV-291. |
Up to 12 Months
|
|
Time to Cmax (Tmax) of ABBV-291
Tidsramme: Up to 12 Months
|
Tmax is defined as time to Cmax of ABBV-291. |
Up to 12 Months
|
|
Half-Life (t1/2) of ABBV-291
Tidsramme: Up to 12 Months
|
t1/2 is defined as the half-life of ABBV-291. |
Up to 12 Months
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: ABBVIE INC., AbbVie
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Lymfesygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom, B-celle
- Lymfom
- Hemiske og lymfatiske sygdomme
- Neoplasmer
- Lymfom, stor B-celle, diffus
- Lymfom, Non-Hodgkin
- Lymfom, follikulært
- Lymfom, kappecelle
- Lymfom, B-celle, marginalzone
Andre undersøgelses-id-numre
- M24-893
- 2024-512586-13-00 (Anden identifikator: EU CT)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .